EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 237 (2026) BIO Web Conf., 237 (2026) 02009 References
Open Access
Issue
BIO Web Conf.
Volume 237, 2026
2026 8th International Conference on Biotechnology and Biomedicine (ICBB 2026)
Article Number 02009
Number of page(s) 14
Section Pharmacology, Natural Products and Drug Delivery
DOI https://doi.org/10.1051/bioconf/202623702009
Published online 10 June 2026
  • G. Bianchini, C. De Angelis, A. Licchetta, and L. Gianni, “Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease,” Nat. Rev. Clin. Oncol., vol. 13, no. 11, pp. 674–690, 2016, doi: 10.1038/nrclinonc.2016.66. [Google Scholar]
  • M. Karim, J. E. Kwon, T. Ali, J. Jang, I. Ullah, Y. Lee, D. W. Park, J. Park, J. W. Jeang, and S. C. Kang, “Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies,” Biochem. Pharmacol., vol. 212, p. 115545, 2023, doi: 10.1016/j.bcp.2023.115545. [Google Scholar]
  • J. Ren, et. al, “P. gingivalis Infection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer,” Cancer Immunol. Res., vol. 11, no. 3, 2023, doi: 10.1158/2326-6066.CIR-22-0541. [Google Scholar]
  • D. Zimmerli, C. S. Brambillasca, F. Talens, J. Bhin, R. Linstra, L. Romanens, A. Bhattacharya, S. E. P. Joosten, A. M. Da Silva, N. Padrao, M. D. Wellenstein, K. Kersten, M. De Boo, M. Roorda, L. Henneman, R. De Bruijn, S. Annunziato, E. Van Der Burg, A. P. Drenth, et al., “MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling,” Nat. Commun., vol. 13, no. 1, 2022, doi: 10.1038/s41467-022-34000-6. [Google Scholar]
  • X. Sun, S. et. al, “Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion,” Nature, vol. 599, pp. 673–678, 2021, doi: 10.1038/s41586-021-04057-2. [Google Scholar]
  • P. Schmid, S. Adams, H. S. Rugo, A. Schneeweiss, C. H. Barrios, H. Iwata, and S. Loi, “Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer,” N. Engl. J. Med., vol. 379, no. 22, pp. 2108–2121, 2020, doi: 10.1056/NEJMoa1809615. [Google Scholar]
  • C. M. Zwolinski, K. S. Ellison, N. DePaola, and D. M. Thompson, “Generation of cell-derived three dimensional extracellular matrix substrates from two dimensional endothelial cell cultures,” Tissue Eng. Part C Methods, vol. 17, no. 5, pp. 589–595, 2011, doi: 10.1089/ten.tec.2010.0619. [Google Scholar]
  • Q. Zuo, Y. Wang, D. Yang, S. Guo, X. Li, J. Dong, C. Wan, Y. Shen, and F. Wen, “Identification of hub genes and key pathways in the emphysema phenotype of COPD,” Aging, vol. 13, no. 4, pp. 5120–5135, 2021, doi: 10.18632/aging.202432. [Google Scholar]
  • Y. Zhang, et al., “Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer,” Cancer Cell, vol. 43, no. 3, pp. 446–463.e7, 2025, doi: 10.1016/j.ccell.2025.01.007. [Google Scholar]
  • F. Mauri, et. al, “NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation,” Nat. Cancer, vol. 2, no. 12, pp. 1150–1165, 2021, doi: https://www.nature.com/articles/s43018-021-00287-5. [Google Scholar]
  • H. Hu, Q. Shen, L. Zhang, S. Zhu, Y. Cheng, H. Duan, F. Zhang, L. Wang, Y. Jin, J. Cao, Y. Wang, and B. Liu, “OH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via β-catenin pathway suppression,” Commun. Biol., vol. 8, no. 1, 2025, doi: 10.1038/s42003-025-08520-y. [Google Scholar]
  • G. Bianchini, C. De Angelis, A. Licchetta, and L. Gianni, “Treatment landscape of triple-negative breast cancer—expanding options, evolving needs,” Nat. Rev. Clin. Oncol., vol. 19, no. 2, pp. 91–113, 2022, doi: 10.1038/s41571-021-00564-4. [Google Scholar]
  • S. Spranger, R. Bao, and T. F. Gajewski, “Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity,” Nature, vol. 523, no. 7559, pp. 231–235, 2015, doi: 10.1038/nature14404. [Google Scholar]
  • J. Yu, C. Zhou, and Y. Li, “β-catenin signaling drives immune evasion in breast cancer,” Front. Immunol., vol. 14, 2023, Art. no. 113456, doi: 10.3389/fimmu.2023.113456. [Google Scholar]
  • T. Todo, R. L. Martuza, S. D. Rabkin, and P. A. Johnson, “Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing,” Proc. Natl. Acad. Sci. U.S.A., vol. 98, no. 11, pp. 6396–6401, 2001, doi: 10.1073/pnas.101136398. [Google Scholar]
  • Melody Riaud. et. al, “The role of CRAF in cancer progression: from molecular mechanisms to precision therapies,” Nat. Rev. Cancer, vol. 24, no. 1, pp. 105–122, 2024, doi: 10.1038/s41568-023-00650-x. [Google Scholar]
  • A. Nie, et al., “NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation,” Nat. Commun., vol. 10, no. 1, 2019, Art. no. 5533, doi: 10.1038/s41467-019-13378-w. [Google Scholar]
  • T. Azad, R. Rezaei, R. Singaravelu, A. Pelin, S. Boulton, J. Petryk, K. A. Onsu, N. T. Martin, V. Hoskin, M. Ghahremani, M. Marotel, R. Marius, X. He, M. J. F. Crupi, H. Hoang, A. Nik-Akhtar, M. Ahmadi, N. K. Zamani, A. Golshani, et al., “Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies,” Nat. Commun., vol. 14, no. 1, 2023, doi: 10.1038/s41467-023-38651-x. [Google Scholar]
  • Z. Zhu, A. J. R. McGray, W. Jiang, B. Lu, P. Kalinski, and Z. S. Guo, “Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways,” Mol. Cancer, vol. 21, no. 1, 2022, doi: 10.1186/s12943-022-0. [Google Scholar]
  • R. Sule, G. Rivera, and A. V. Gomes, “Western blotting (immunoblotting): History, theory, uses, protocol and problems,” BioTechniques, vol. 75, no. 3, pp. 99–114, 2023, doi: 10.2144/btn-2022-0034. [Google Scholar]
  • Z. Sun, et al., “Commentary: Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma” Front. Immunol., vol. 15, 2024, doi: 10.3389/fimmu.2024.1377221 [Google Scholar]
  • D. Chen, et al., “T follicular helper and T follicular regulatory cells in colorectal cancer: A complex interplay” J. Immunol. Methods, vol. 480, p. 112753, 2020, doi: 10.1016/j.jim.2020.112753. [Google Scholar]
  • K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001, doi: 10.1006/meth.2001.1262. [Google Scholar]
  • Y. Liu, L. Miao, W. Gao, et al., “A survivin promoter- based conditionally replicative adenovirus that selectively targets tumor cells,” Mol. Ther., vol. 9, no. 4, pp. 499–509, 2004, doi: 10.1016/j.ymthe.2004.01.010. [Google Scholar]
  • GraphPad Software, “GraphPad Prism version 9.0 for Windows,” San Diego, CA: GraphPad Software, 2020. [Online]. Available: https://www.graphpad.com [Google Scholar]
  • Y. Qiao, et al., “Mast cell degranulation in tumor- immune microenvironment,” Nat. Immunol., vol. 22, no. 9, pp. 1102–1112, 2021, doi: https://www.nature.com/articles/s41590-019-0321-5. [Google Scholar]
  • Promega Corporation, Dual-Luciferase® Reporter Assay System Technical Manual, Madison, WI, USA, 2022. [Google Scholar]
  • H. J. Motulsky and R. E. Brown, “Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate,” BMC Bioinformatics, vol. 7, no. 123, pp. 1–20, 2006. [Google Scholar]
  • D. Liu, et al., “Integrative molecular and clinical modeling of outcomes to PD1 blockade in patients with metastatic melanoma,” Nat. Med., vol. 25, no. 12, pp. 1916–1927, 2018, doi: 10.1038/s41591-018-0329-4. [Google Scholar]
  • Q. Chen, M. Khoury, and J. Chen, “Expression of human cytokines dramatically improves reconstitution of myeloid cells in humanized NSG mice,” Blood Adv., vol. 3, no. 4, pp. 570–584, 2019, doi: 10.1182/bloodadvances.2018024170. [Google Scholar]
  • Perl, S. Wert, A. Nagy, C. Lobe, and J. Whitsett, “Early restriction of peripheral and proximal cell lineages during formation of the lung,” Proc. Natl. Acad. Sci. U.S.A., vol. 99, no. 16, pp. 10482–10487, 2002, doi: 10.1073/pnas.152239599. [Google Scholar]
  • X. Wang, Y. Li, Y. Dai, et al., “TRPM8: a potential target for cancer treatment” J. Cancer Res. Clin. Oncol., vol. 142, no. 9, pp. 1871–1881, 2016, doi: 10.1007/s00432-015-2112-1. [Google Scholar]
  • K. Kos, et al., “Neutrophils create a fertile soil for metastasis,” Cancer Cell, vol. 39, no. 3, pp. 450–464, fimmu.2023.1134562021, doi: 10.1016/j.ccell.2021.01.009. [Google Scholar]
  • S. Shang, et al., “ID1 expressing macrophages support cancer cell stemness and limit CD8⁺ T cell infiltration in colorectal cancer,” Nat. Commun., vol. 14, no. 1, 2023, doi: 10.1038/s41467-023-43548-w. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.